Management accounting quarterly · 2012 · 10 citations · 0 references
BusinessAccountancyAccountingCorporate DisclosureCorporate ReportingFinancial AccountingFinancial ReportingFinancial Reporting ObjectivesFinancial Reporting RequirementsFinancial StatementsRisk ReportingStatement Of Cash FlowsCorporate Disclosure StandardsSarbanes-oxley Compliance
At 12 months, bimonthly and T&E ranibizumab were noninferior to PRN in naïve nAMD.